First published in 1987: This book is intended as a guide for a very large group of practitioners in the medical, pharmaceutical, and biological fields. It will enable them to prescribe and use antibiotics in an improved way.
Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.
The use of drugs in food animal production has resulted in benefits throughout the food industry; however, their use has also raised public health safety concerns. The Use of Drugs in Food Animals provides an overview of why and how drugs are used in the major food-producing animal industriesâ€"poultry, dairy, beef, swine, and aquaculture. The volume discusses the prevalence of human pathogens in foods of animal origin. It also addresses the transfer of resistance in animal microbes to human pathogens and the resulting risk of human disease. The committee offers analysis and insight into these areas: Monitoring of drug residues. The book provides a brief overview of how the FDA and USDA monitor drug residues in foods of animal origin and describes quality assurance programs initiated by the poultry, dairy, beef, and swine industries. Antibiotic resistance. The committee reports what is known about this controversial problem and its potential effect on human health. The volume also looks at how drug use may be minimized with new approaches in genetics, nutrition, and animal management.
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.
Antimicrobial Stewardship (AMS), Volume Two includes the experience of ESGAP workshops and courses on antibiotic stewardship since 2012. It combines clinical and laboratory information about AMS, with a focus on human medicine. The ESCMID study group on antibiotic policies (ESGAP) is one of the most productive groups in the field, organizing courses and workshops. This book is an ideal tool for the participants of these workshops. With short chapters (around 1500 words) written on different topics, the authors insisted on the following points: A 'hands on', practical approach, tips to increase success, a description of the most common mistakes, a global picture (out- and inpatient settings, all countries) and a short list of 10-20 landmark references. - Focuses on the most recent antimicrobial stewardship strategies - Provides a detailed description of laboratory support - Offers a balanced synthesis of basic and clinical sciences for each individual case, presenting clinical courses of the cases in parallel with the pathogenesis and detailed microbiological information for each infection - Describes the prevalence and incidence of the global issues and current therapeutic approaches - Presents the measures for infection control
Although the potential for immunomodulation has been recognized for many years there has been an explosion of data in this field with relevance especially to the treatment of chronic airway diseases. Most of the work in this field has been conducted by Japanese investigators but in the last decade there has been a body of work outside of Japan that supports and enhances these findings. The book covers basic research like effects on bacteria, anti-inflammatory and mucoregulatory effects, but also clinical results with up-to-date information for the use of such medications to potentially treat diseases as diverse as chronic airway diseases, arthritis, inflammatory bowel disease, and cancer. The volume is intended for pulmonary physicians, researchers in inflammation research, and pharmaceutical companies interested in the development of such agents. It provides background information for the clinician as well as in depth exploration of cutting edge science.
Antibiotics and Antimicrobial Resistance Genes (AMR) in the Environment summarizes and updates information on antibiotic producing organisms and their resistance and entry routes in soil, air, water and sediment. As antibiotic use continues to rise in healthcare, their fate, bioavailability and biomonitoring, and impacts on environment and public health are becoming increasingly important. The book addresses the impact of antibiotics and AMR to environment and public health and risk assessment. Moreover, it focused on the metagenomics and molecular techniques for the detection of antibiotics and antimicrobial genes. Lastly, it introduces management strategies, such as treatment technologies for managing antibiotics and AMR/ARGs-impacted environment, and bioremediation approaches. - Summarizes and updates information on antibiotics and AMR/ARGs production and its fate and transport in the environment - Includes phytoremediation and bioremediation technologies for environmental management - Provides analysis of risk assessment of antibiotic resistance genes to help understand the environmental and socioeconomic impacts of antibiotics and AMR/ARGs